Evotec SE (EVO) Liabilities and Shareholders Equity (2009 - 2026)
Evotec SE (EVO) reported Liabilities and Shareholders Equity of $1.9 million for Q1 2026, down 6.16% on a YoY basis from $2.0 million in Q1 2025, and up 96125.58% sequentially from $1995.1 in Q4 2025.
Evotec SE (EVO) Liabilities and Shareholders Equity (2009 - 2026) Analysis & Trends
Evotec SE (EVO) has 10 years of Liabilities and Shareholders Equity data on file, last reported at $1.9 million in Q1 2026.
- For the quarter ending Q1 2026, Liabilities and Shareholders Equity fell 6.16% year-over-year to $1.9 million; the trailing twelve-month figure through Mar 2026 stood at $6.0 million (down 100.0% YoY), and the FY2025 full-year result was $1995.1, down 100.0% from the prior year.
- Liabilities and Shareholders Equity rose to $1.9 million in Q1 2026, from $1995.1 in the prior quarter.
- In the past five years, Liabilities and Shareholders Equity ranged from a high of $2452.3 billion in Q1 2022 to a low of $1995.1 in Q4 2025.
- A 5-year average of $586.7 billion and a median of $22.8 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
- Across the five-year window, Liabilities and Shareholders Equity soared 4610.0% in 2024 and sank 100.0% in 2025, its largest moves.
- Tracing EVO's Liabilities and Shareholders Equity over 5 years: stood at $55.0 million in 2022, then declined by 21.06% to $43.4 million in 2023, then soared by 4610.0% to $2.0 billion in 2024, then slumped by 100.0% to $1995.1 in 2025, then jumped by 96125.58% to $1.9 million in 2026.
- Business Quant data shows EVO's Liabilities and Shareholders Equity at $1.9 million in Q1 2026, $1995.1 in Q4 2025, and $2.1 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 89.28 Bn | 87.42 Bn | - | 43.40 Bn |
| 2 | Teva Pharmaceutical Industries | 35.97 Bn | 32.23 Bn | 1.97 Bn | 40.04 Bn |
| 3 | Zoetis | 32.42 Bn | 30.48 Bn | 1.62 Bn | 15.15 Bn |
| 4 | Takeda Pharmaceutical | 27.48 Bn | 23.42 Bn | 4.39 Bn | 98.91 Bn |
| 5 | United Therapeutics | 22.89 Bn | 20.73 Bn | 648.10 Mn | 6.71 Bn |
| 6 | RedHill Biopharma | 22.11 Bn | 22.11 Bn | - | 25.35 Mn |
| 7 | Viatris | 20.44 Bn | 18.64 Bn | 1.16 Bn | 36.83 Bn |
| 8 | Neurocrine Biosciences | 17.76 Bn | 16.44 Bn | 800.70 Mn | 4.91 Bn |
| 9 | Elanco Animal Health | 12.62 Bn | 12.19 Bn | 785.00 Mn | 13.22 Bn |
| 10 | Evotec SE | 339.17 Mn | 338.65 Mn | - | 1.92 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.92 Mn |
| Dec 31, 2025 | 1,995.11 |
| Sep 30, 2025 | 2.07 Mn |
| Jun 30, 2025 | 2.05 Mn |
| Mar 31, 2025 | 2.05 Mn |
| Dec 31, 2024 | 2.04 Bn |
| Sep 30, 2024 | 2,186.35 Bn |
| Mar 31, 2024 | 2,399.39 Bn |
| Dec 31, 2023 | 43.39 Mn |
| Dec 31, 2022 | 54.97 Mn |
| Sep 30, 2022 | 2.28 Mn |
| Mar 31, 2022 | 2,452.33 Bn |
| Dec 31, 2021 | 29.12 Mn |
| Sep 30, 2021 | 2,084.80 Bn |
| Dec 31, 2020 | 23.00 Mn |
| Dec 31, 2019 | 12.69 Mn |
| Sep 30, 2010 | 230,107.36 |
| Jun 30, 2010 | 192,993.83 |
| Mar 31, 2010 | 200.13 Mn |
| Dec 31, 2009 | 216,487.76 |